Inovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Inovio (INO) Bullish Stance Reiterated at Maxim Group Amid MERS Trial Patient Recruitment and Zika Vaccine Progress
January 28, 2016 11:18 AM ESTMaxim Group analyst Jason McCarthy reiterated his Buy rating and $14 price target on Inovio Pharmaceuticals (NASDAQ: INO) as MERS vaccine trial initiates patient recruitment and amid progress on a vaccine targeting the Zika Virus.
The analyst highlighted:
Inovio and partner GeneOne Life Science (KSE:011000-NR) announced that the phase I study of GLS-5300 (vaccine targeting MERS, Middle East Respiratory... More